Edgewise Therapeutics, Inc. EWTX · Stock Open Edgewise Therapeutics, Inc. in new tab
Edgewise Therapeutics, Inc. Analysis (EWTX)
Is Edgewise Therapeutics, Inc. a good investment? Edgewise Therapeutics, Inc. (EWTX) is currently trading at 38.38 USD. Market analysts have a consensus price target of 49.92 USD. This suggests a potential upside from current levels.
Earnings Schedule: Edgewise Therapeutics, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -1.47.
Investor FAQ
Does Edgewise Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Edgewise Therapeutics, Inc.?
Edgewise Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.66.
Company Profile
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Community Discussion